ArticleBritish journal of cancer2013
Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Impact of targeting the platelet-activating factor and its receptor in cancer treatment.Military Medical Research · 2025Review
- Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating Pregnancy.Kidney & blood pressure research · 2025Article
- Review
- Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways.Frontiers in oncology · 2021Article
- LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.PloS one · 2020Article
- LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.Journal of experimental & clinical cancer research : CR · 2019Article
- Phospholipid Remodeling in Physiology and Disease.Annual review of physiology · 2019Review
- Platelet activating factor receptor antagonists improve the efficacy of experimental chemo- and radiotherapy.Clinics (Sao Paulo, Brazil) · 2018Review
- In vivo RNAi screening identifiesBlood advances · 2018Article
- Inflammation, not Cholesterol, Is a Cause of Chronic Disease.Nutrients · 2018Review
- PAFR selectively mediates radioresistance and irradiation-induced autophagy suppression in prostate cancer cells.Oncotarget · 2017Article
- Quebrachitol: Global Status and Basic Research.Natural products and bioprospecting · 2017Review
- Targeting of cytosolic phospholipase A2α impedes cell cycle re-entry of quiescent prostate cancer cells.Oncotarget · 2015Article
- Hypoxia induces a lipogenic cancer cell phenotype via HIF1α-dependent and -independent pathways.Oncotarget · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet-activating factor (PAF) is an arachidonic acid metabolite that plays an important role in cell proliferation, migration and neoangiogenesis, but whether it is involved in the progression of prostate cancer remains undiscovered.
methodsClinical prostate specimens were investigated with immunohistochemistry method and in vitro cell experiments referred to MTS cell proliferation assay, invasion and migration experiment, quantitative real-time RT-PCR assay, western blotting analysis and ELISA assay.
resultsPlatelet-activating factor synthetase, lyso-PAF acetyl transferase (LPCAT1), increased significantly in castration-resistant prostate cancer (CRPC) specimens and CRPC PC-3 cells than that in controls. Intriguingly, PAF induced invasion and migration of PC-3 cells but not LNCaP cells. The PAF receptor antagonist inhibited proliferation of LNCaP and PC-3 cells. Dihydrotestosterone (DHT) treatment caused a decrease in LPCAT1 expression and PAF release in LNCaP cells, which could be blocked by androgen receptor antagonists. Finally, DHT increased LPCAT1 expression and PAF release in PC-3 cells in a Wnt/β-catenin-dependent manner.
conclusionFor the first time, our data supported that PAF might play pivotal roles in the progression of prostate cancer, which might throw a new light on the treatment of prostate cancer and the prevention of the emergence of CRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.